Genflow Biosciences announced it has signed a master service agreement with Contract Research Organization CER to deepen their long-term R&D collaboration. According to the company, the agreement will support ongoing and future projects focused on developing therapies aimed at extending healthy lifespan.
The company said the partnership will include preclinical research and development activities for its gene therapy programs targeting aging-related conditions. Genflow Biosciences claims its lead candidate, GF-1002, is designed to deliver a variant of the SIRT6 gene associated with longevity and DNA repair.
CER will provide contract research services to advance these programs through preclinical stages. According to the company, the collaboration is expected to streamline research operations and enhance the quality of experimental data.
Genflow Biosciences said the agreement builds on an existing working relationship between the two organizations. The company claims this expanded partnership aligns with its strategic plan to accelerate the translation of scientific discoveries into therapies targeting aging and age-related diseases.
The company said it remains focused on advancing its pipeline of gene therapies, which it claims could address underlying mechanisms of biological aging and improve healthspan.
